Malignant Esophageal Neoplasm — Trials

Malignant Esophageal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 518
Recruiting: 303
Ph III recruiting: 41
Growth YoY: +3.3%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.5%
Trials / 1,000 deaths: 32.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 1,101–1,150 of 1,926 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04060342	GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma	terminated	Phase 1	61	GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY	2	Aug 18, 2022	clinicaltrials
NCT04699994	Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel	unknown	Phase 2	60	Keio UniversityOTHER	1